AI assistant
Ocugen, Inc. — Director's Dealing 2019
Dec 16, 2019
32915_dirs_2019-12-16_2f8b4552-e525-4b52-a900-efa48afb7709.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Ocugen, Inc. (OCGN)
CIK: 0001372299
Period of Report: 2019-09-27
Reporting Person: Beck Kelly (Vice President)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Options (right to buy) | $7.56 | 2027-07-10 | Common stock (14382) | Direct | |
| Stock Options (right to buy) | $7.56 | 2027-12-15 | Common Stock (11985) | Direct | |
| Stock Options (right to buy) | $13.52 | 2028-12-07 | Common Stock (9588) | Direct |
Footnotes
F1: 9,588 Stock Options became exercisable immediately, and the remaining 4,794 Warrants will become exercisable on July 9, 2020, subject to continued employment with Ocugen, Inc. (the "Company").
F2: 3,995 Stock Options became exercisable immediately, and the remaining 7,990 Warrants will become exercisable 50% each on December 15, 2019 and December 14, 2020, subject to continued employment with the Company through the applicable vesting date.
F3: The Stock Options will become exercisable 1/3 each on December 7, 2019, December 7, 2020 and December 6, 2021, subject to continued employment with the Company through the applicable vesting date.